Jay Bradner’s NIBR exit sets off a succession plan at Merck; Dyne and MorphoSys fill major R&D roles
→ In the Big Pharma world, companies like J&J and Merck have experienced a pronounced sea change in leadership over a two-year period, and you …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
